The accuracy of [ 18F]fluorodeoxyglucose positron emission tomography as confirmed by biopsy in the diagnosis of spine metastases in a cancer population

Neurosurgery

Volumn 64, Issue 1, 2009, Pages 107-113

  Laufer, Ilya ^a,b   Lis, Eric ^a   Pisinski, Leszek ^c   Akhurst, Timothy ^a   Bilsky, Mark H ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c HARLEM HOSPITAL CENTER   (United States)

Author keywords

18F Fluorodeoxyglucose; Metastasis; Positron emission tomography; Sclerotic; Screening; Solid tumor; Spine; Vertebral

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BENIGN TUMOR; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOLID TUMOR; SPINAL CORD LESION; SPINE METASTASIS; METASTASIS; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING; SPINAL CORD TUMOR;

BIOPSY, NEEDLE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SPINAL NEOPLASMS;

EID: 62449300719     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000335176.98788.A1     Document Type: Article

References (24)

1. Bilsky MH, Shannon FJ, Sheppard S, Prabhu V, Boland PJ: Diagnosis and management of a metastatic tumor in the atlantoaxial spine. Spine 27:1062-1069, 2002.
2. Blodgett TM, Meltzer CC, Townsend DW: PET/CT: Form and function. Radiology 242:360-385, 2007.
3. Bohdiewicz PJ, Wong CY, Kondas D, Gaskill M, Dworkin HJ: High predictive value of F-18 FDG PET patterns of the spine for metastases or benign lesions with good agreement between readers. Clin Nucl Med 28:966-970, 2003.
4. 18F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment? Hematol Oncol Clin North Am 21:855-869, 2007.
5. Breyer RJ 3rd, Mulligan ME, Smith SE, Line BR, Badros AZ: Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 35:632-640, 2006.
6. Cook GJ, Fogelman I: The role of positron emission tomography in the management of bone metastases. Cancer 88:2927-2933, 2000.
7. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I: Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998.
8. 18F]fluorodeoxyglucose positron-emission tomography/ computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 25:3440-3447, 2007.
9. 18F-FDG PET in oncology. J Nucl Med 49:480-508, 2008.
10. Fogelman I, Cook G, Israel O, Van der Wall H: Positron emission tomography and bone metastases. Semin Nucl Med 35:135-142, 2005.
11. Ghanem N, Uhl M, Brink I, Schafer O, Kelly T, Moser E, Langer M: Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 55:41-55, 2005.
12. 18F] FDG-PET in the assessment of bone marrow infiltration of the spine in cancer patients. Eur Spine J 16:1907-1912, 2007.
13. Guise TA: Bone loss and fracture risk associated with cancer therapy. Oncologist 11:1121-1131, 2006.
14. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K: Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 31 [Suppl 1]:S125-S134, 2004.
15. Lis E, Bilsky MH, Pisinski L, Boland P, Healey JH, O'Malley B, Krol G: Percutaneous CT-guided biopsy of osseous lesion of the spine in patients with known or suspected malignancy. AJNR Am J Neuroradiol 25:1583-1588, 2004.
16. 18F-FDG PET/CT. J Nucl Med 45:279-284, 2004.
17. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, Suzuki T, Nishimura T: Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32:1253-1258, 2005.
18. Peterson JJ, Kransdorf MJ, O'Connor MI: Diagnosis of occult bone metastases: Positron emission tomography. Clin Orthop Relat Res 415 [Suppl]:S120-S128, 2003.
19. 18F-FDG PET/CT. J Nucl Med 47:1274-1280, 2006.
20. Schmidt G P, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A: Screening for bone metastases: Whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939-949, 2007.
21. Schmitz A, Risse JH, Textor J, Zander D, Biersack HJ, Schmitt O, Palmedo H: FDG-PET findings of vertebral compression fractures in osteoporosis: Preliminary results. Osteoporos Int 13:755-761, 2002.
22. Shreve PD, Grossman HB, Gross MD, Wahl RL: Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology 199:751-756, 1996.
23. Wise JJ, Fischgrund JS, Herkowitz HN, Montgomery D, Kurz LT: Complication, survival rates, and risk factors of surgery for metastatic disease of the spine. Spine 24:1943-1951, 1999.
24. 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging, and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92:50-55, 2007.